Why the study?
There are no approved antivirals available to treat parechovirus or other picornavirus infections, prompting a structural and functional comparison of cleaved polyprotein products to inform drug development.
Highlights structural differences between parechoviruses and other picornaviruses to guide specific antiviral drug development.
No approved antivirals for parechovirus; leaves open urgent need for targeted therapeutic development in neonates.
Parechoviruses belong to the genus Parechovirus within the family Picornaviridae and are non-enveloped icosahedral viruses with a single-stranded RNA genome. Parechoviruses include human and animal pathogens classified into six species. Those that infect humans belong to the Parechovirus A species and can cause infections ranging from mild gastrointestinal or respiratory illness to severe neonatal sepsis. There are no approved antivirals available to treat parechovirus (nor any other picornavirus) infections. In this parechovirus review, we focus on the cleaved protein products resulting from the polyprotein processing after translation comparing and contrasting their known or predicted structures and functions to those of other picornaviruses. The review also includes our original analysis from sequence and structure prediction. This review highlights significant structural differences between parechoviral and other picornaviral proteins, suggesting that parechovirus drug development should specifically be directed to parechoviral targets.
No takes yet. Share an insight, caveat, or question.
Domanska et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: